N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450

Drug Metabolism and Disposition

Volumn 26, Issue 6, 1998, Pages 566-571

  Hashizume, Takanori ^a   Mise, Masashi ^b   Terauchi, Yoshiaki ^b   O, Luan ^b   Fujii, Toshihiko ^b   Miyazaki, Hisashi ^b   Inaba, Tadanobu ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BUTYROPHENONE DERIVATIVE; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; EBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; MIDAZOLAM; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; DEALKYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BUTYROPHENONES; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; HISTAMINE H1 ANTAGONISTS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; PIPERIDINES;

EID: 0031791944     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Back DJ, Tjia JF, Karbwang J and Colbert J (1988) In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 26:23-29.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenabiotica 25:261-270.
3. Campbell ME, Grant DM, Inaba T and Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15:237-249.
4. Chang TKH, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Arch Biochem Biophys 311:437-442.
5. 14C]ebastine after a single administration in rats. Arzneim Forsch 44:527-538.
6. Geary WJ III, Garcia JD and Dockhorn RJ (1995) Electrocardiographic safety of 10 mg of ebastine in healthy elderly and young adult volunteers. Allergy 50(Suppl):199.
7. Guengerich FP, Kim DH and Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
8. Heyn H, White RB and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of. S-mephenytoin. Drug Metab Dispos 24:948-954.
9. Honig PK, Woosley RL, Zamani K, Conner DP and Cantilena LR (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231-238.
10. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE and Cantilena LR (1993a) Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 33:1201-1206.
11. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993b) Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518.
12. Hopes H, Meuret GH, Ungethum W, Leopold G and Wiemann H (1992) Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG. Eur J Clin Pharmacol 42:55-59.
13. Inaba T, Jurima M, Mahon WA and Kalow W (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13:443-448.
14. 3-hydroxylation. Drug Metab Dispos 16:605-608.
15. Jurima-Romet M, Crawford K, Cyr T and Inaba T (1989) Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857.
16. Kawashima H, Kusunose E, Kikuta Y, Kinoshita H, Tanaka S, Yamamoto S, Kishimoto T and Kusunose M (1994) Purification and cDNA cloning of human liver CYP4A fatty acid ω-hydroxylase. J Biochem (Tokyo) 116:74-80.
17. Kivisto KT, Neuvonen PJ and Klotz U (1994) Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 27:1-5.
18. 1-receptor antagonists in the management of allergic rhinitis: a comparative review. Clin Immunother 2:352-375.
19. Kronbach T, Fischer V and Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630-635.
20. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
21. Kukita A, Kawashima M and Harada S (1994) Clinicopharmacological study of LAS-90: inhibitory effect on wheal and erythema induced by intradermal injection of histamine. J Clin Ther Med 10(Suppl 1):103-111.
22. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656.
23. Ling K-HJ, Leeson GA, Burmaster SD, Hook RH, Reith MK and Cheng LK (1995) Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23:631-636.
24. 1-receptor antagonist. Drugs Today 28(Suppl B):11-21.
25. Martinez-Tobed A, Tarrus E, Segura J and Roberts DJ (1992) Pharmacokinetic studies of ebastine in rats, dogs and man. Drugs Today 28(Suppl):57-67
26. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J and Maurel P (1992) Effects of imidazole derivatives on cytochrome P450 from human hepatocytes in primary culture. FASEB J 6:752-758.
27. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J and Cantilena LR (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-2790.
28. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
29. Nunoya K, Yokoi T, Kimura K, Kodama T, Funayama M, Inoue K, Nagashima K, Funae Y, Shimada N, Green C and Kamataki T (1996) (+)-is-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J Pharmacol Exp Ther 277:768-774.
30. Pessayre D, Tinel M, Larrey D, Cobert B, Funck-Brentano C and Babany G (1983) Inactivation of cytochrome P-450 by a troleandomycin metabolite: protective role of glutathione. J Pharmacol Exp Ther 224:685-691.
31. Reidy GF, Mehta I and Murray M (1989) Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 35:736-743.
32. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS and Estabrook RW (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase: comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23:765-775.
33. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R and Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651-663.
34. Shimada T, Yamazaki M, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
35. Stevens JC, Berger PL and Bordeaux KG (1993) Metabolism of ebastine by human liver microsomes and cDNA-expressed cytochrome P450 forms, in Abstracts of the 5th European ISSX Meeting, vol 3, p 66, International Society for the Study of Xenobiotics, Bethesda, MD.
36. Tyndale RF, Inaba T and Kalow W (1989) Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P-450IID1) in vitro. Drug Metab Dispos 17:334-340.
37. Vincent J, Liminana R, Merendith PA and Reid JL (1988a) The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 26:497-502.
38. Vincent J, Sumner DJ and Reid JL (1988b) Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br J Clin Pharmacol 26:503-508.
39. Waxman DJ, Attisano C, Guengerich FP and Lapenson DP (1988) Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263:424-436.
40. Wiseman LR and Faulds D (1996) Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 51:260-277.
41. Yakuo I, Ishii K, Seto Y, Imano K, Takeyama K, Nakamura H and Karasawa T (1994) Pharmacological study of ebastine, a novel histamine H1-receptor antagonist. Folia Pharmacol Jpn 103:121-135.
42. 1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneim-Forsch 44:59-64.
43. Yun C-H, Okerholm RA and Guengerich FP (1993) Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 21:403-409.
44. Yun C-H, Shimada T and Guengerich FP (1991) Purification and characterization of human microsomal cytochrome P450 2A6. Mol Pharmacol 40:679-685.